Core Viewpoint - Pelthos Therapeutics has secured a financing deal with Horizon Technology Finance Corporation, providing an initial funding of $30 million and potential additional funding of up to $20 million to support the commercialization of its product portfolio, particularly ZELSUVMI, the first FDA-approved treatment for molluscum contagiosum for home use [1][2][4]. Financing Details - The financing includes an initial $30 million, with an additional $20 million contingent on achieving specific milestones. The interest rate is Prime plus 3.75%, currently at 10.50%, and the term is sixty months with amortization beginning at month thirty-six [4]. - Pelthos issued warrants to Horizon for the purchase of 65,488 shares of common stock at an exercise price of $27.49 per share as part of the financing agreement [4]. Product Focus - The funds will be utilized to support the commercialization of ZELSUVMI™, launch Xepi®, and Xeglyze®, as well as for working capital and general corporate purposes [4]. - ZELSUVMI™ is highlighted as a significant product for treating molluscum contagiosum, addressing a persistent and difficult-to-treat infection, particularly for children and families [2][6]. Company Financials - As of September 30, 2025, Pelthos had cash, cash equivalents, and investments totaling $14.2 million, which was supplemented by the issuance of $18.0 million in convertible notes in November 2025 [7]. Strategic Partnerships - Horizon Technology Finance Corporation expresses confidence in Pelthos' management team and their commitment to advancing therapies for underserved cutaneous indications, indicating a strong partnership moving forward [3].